Stock Research for INCY


Featured Broker: Ally Invest

Get the due diligence for another stock.


INCY Stock Chart & Research Data

The INCY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INCY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


INCY Due diligence Resources & Stock Charts

The INCY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INCY Detailed Price Forecast - CNN Money CNN View INCY Detailed Summary - Google Finance
Yahoo View INCY Detailed Summary - Yahoo! Finance Zacks View INCY Stock Research & Analysis -

Stock Analysis

TradeIdeas View INCY Trends & Analysis - Trade-Ideas Barrons View INCY Major Holders - Barrons
NASDAQ View INCY Call Transcripts - NASDAQ Seeking View INCY Breaking News & Analysis - Seeking Alpha
Spotlight View INCY Annual Report - OTC Report View INCY OTC Short Report -
TradeKing View INCY Fundamentals - TradeKing Charts View INCY SEC Filings - Bar Chart
WSJ View Historical Prices for INCY - The WSJ Morningstar View Performance/Total Return for INCY - Morningstar
MarketWatch View the Analyst Estimates for INCY - MarketWatch CNBC View the Earnings History for INCY - CNBC
StockMarketWatch View the INCY Earnings - StockMarketWatch MacroAxis View INCY Buy or Sell Recommendations - MacroAxis
Bullish View the INCY Bullish Patterns - American Bulls Short Pains View INCY Short Pain Metrics -

Social Media Mentions

StockTwits View INCY Stock Mentions - StockTwits PennyStocks View INCY Stock Mentions - PennyStockTweets
Twitter View INCY Stock Mentions - Twitter Invest Hub View INCY Investment Forum News - Investor Hub
Yahoo View INCY Stock Mentions - Yahoo! Message Board Seeking Alpha View INCY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for INCY - Insider Cow View Insider Transactions for INCY - Insider Cow
CNBC View INCY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INCY - OTC Markets
Yahoo View Insider Transactions for INCY - Yahoo! Finance NASDAQ View Institutional Holdings for INCY - NASDAQ

Stock Charts

FinViz View INCY Stock Insight & Charts - StockCharts View INCY Investment Charts -
BarChart View INCY Stock Overview & Charts - BarChart Trading View View INCY User Generated Charts - Trading View

Latest Financial News for INCY

Incyte (INCY) Announces Positive Results on Jakafi for GVHD
Posted on Friday June 22, 2018

Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event
Posted on Thursday June 21, 2018

Incyte Corporation (INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company’s growth opportunities and late-stage development portfolio. “The presentations today are intended to highlight our diversified development portfolio and its potential to accelerate our top-line growth in the near term,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “The success of the REACH1 study of Jakafi in steroid-refractory acute graft-versus-host disease (GVHD) announced earlier today is excellent news for patients, and also further reinforces the potential of JAK inhibition in GVHD and our development strategy to address this devastating disease.

Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
Posted on Thursday June 21, 2018

Incyte Corporation (INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28. In addition, the best overall response rate (BORR), the number of patients achieving a response at any time point during the study, was 73 percent (n=52/71).

Former Incyte CEO Buys Slumping Nektar Shares
Posted on Monday June 11, 2018

Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...

Enter a stock symbol to view the stock details.